Caribou Biosciences Gestione

Gestione criteri di controllo 2/4

Caribou Biosciences Il CEO è Rachel Haurwitz, nominato in Oct2011, e ha un mandato di 13.08 anni. la retribuzione annua totale è $ 3.12M, composta da 20% di stipendio e 80% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.044% delle azioni della società, per un valore di $ 80.79K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3 anni e 3.5 anni.

Informazioni chiave

Rachel Haurwitz

Amministratore delegato

US$3.1m

Compenso totale

Percentuale dello stipendio del CEO	20.0%
Mandato del CEO	13.1yrs
Proprietà del CEO	0.04%
Durata media del management	3yrs
Durata media del Consiglio di amministrazione	3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Nov 05

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Sep 30

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Sep 06

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Jul 26

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Jul 03

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Jun 05

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Apr 18

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Apr 17

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Feb 15

Caribou Biosciences: Under The Radar With Catalysts Approaching

Feb 01

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Jan 10

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Nov 18

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Feb 24

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Oct 12

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Sep 16

Caribou Biosciences: Potential To Change CAR-T Landscape

Aug 01

Crispred CAR-T Cells In The Clinic

May 19

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 13

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Rachel Haurwitz rispetto agli utili di Caribou Biosciences?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$148m
Jun 30 2024	n/a	n/a	-US$123m
Mar 31 2024	n/a	n/a	-US$115m
Dec 31 2023	US$3m	US$623k	-US$102m
Sep 30 2023	n/a	n/a	-US$95m
Jun 30 2023	n/a	n/a	-US$111m
Mar 31 2023	n/a	n/a	-US$108m
Dec 31 2022	US$833k	US$513k	-US$99m
Sep 30 2022	n/a	n/a	-US$91m
Jun 30 2022	n/a	n/a	-US$85m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$6m	US$527k	-US$67m
Sep 30 2021	n/a	n/a	-US$63m
Jun 30 2021	n/a	n/a	-US$50m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$664k	US$450k	-US$34m
Dec 31 2019	US$540k	US$425k	-US$23m

Compensazione vs Mercato: La retribuzione totale di Rachel ($USD 3.12M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.48M ).

Compensazione vs guadagni: La retribuzione di Rachel è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Rachel Haurwitz (38 yo)

13.1yrs

Mandato

US$3,116,547

Compensazione

Dr. Rachel E. Haurwitz, Ph D., has been the President and Chief Executive Officer at Caribou Biosciences, Inc. since October 2011. She served as independent Director at Seer, Inc. since December 21, 2023 u...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Rachel Haurwitz	Co-Founder	13.1yrs	US$3.12m	0.044% $ 80.8k
Steven Kanner	Chief Scientific Officer	7.4yrs	US$1.22m	0.39% $ 715.1k
Barbara McClung	Chief Legal Officer & Corporate Secretary	9.6yrs	US$1.22m	0.42% $ 760.7k
Ryan Fischesser	Interim Principal Accounting Officer	less than a year	Nessun dato	0.078% $ 142.3k
Daniel Poon	Vice President of Operations & Information Technology	2.4yrs	Nessun dato	Nessun dato
Timothy Kelly	Chief Technology Officer	less than a year	Nessun dato	Nessun dato
Amy Figueroa	Vice President of Investor Relations & Corporate Communications	3yrs	Nessun dato	Nessun dato
Reigin Zawadzki	Chief People Officer	1.2yrs	Nessun dato	Nessun dato
Ruhi Khan	Chief Business Officer	3yrs	US$1.04m	0% $ 0

3.0yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di CRBU è considerato esperto (durata media dell'incarico 3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rachel Haurwitz	Co-Founder	13.1yrs	US$3.12m	0.044% $ 80.8k
Andrew Guggenhime	Independent Chairman	3.6yrs	US$202.74k	0% $ 0
Jennifer Doudna	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Scott Braunstein	Independent Director	3.4yrs	US$155.86k	0% $ 0
Katy Rezvani	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Martin Jinek	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Natalie Sacks	Independent Director	6.5yrs	US$136.99k	0% $ 0
Cameron Turtle	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ran Zheng	Independent Director	3.2yrs	US$157.20k	0% $ 0
Nancy Whiting	Independent Director	3.3yrs	US$140.62k	0% $ 0
Noopur Raje	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ami Bhatt	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

3.5yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CRBU sono considerati esperti (durata media dell'incarico 3.5 anni).

Caribou Biosciences Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Caribou Biosciences Appoints Tina Albertson as Chief Medical Officer

Caribou Biosciences, Inc. Appoints Terri Laufer to Its Scientific Advisory Board

Caribou Biosciences, Inc., Annual General Meeting, Jun 13, 2024

Chief Scientific Officer exercised options to buy US$212k worth of stock.

Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer

Recent updates

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Caribou Biosciences, Inc

Price target increased by 11% to US$17.29

Consensus revenue estimates decrease by 18%, EPS upgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Insufficient new directors

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Caribou Biosciences Announces the Fda Has Granted Fast Track Designations to Cb-010 in Refractory Sle and to Cb-012 in Relapsed or Refractory Aml

Caribou Biosciences Appoints Tina Albertson as Chief Medical Officer

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Caribou Biosciences, Inc. Appoints Terri Laufer to Its Scientific Advisory Board

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Price target decreased by 16% to US$16.63

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Caribou Biosciences, Inc. Presents Encouraging Clinical Data from CB-010 Antler Phase 1 Trial in Second-Line Lbcl Patients At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

First quarter 2024 earnings: EPS misses analyst expectations

Caribou Biosciences, Inc., Annual General Meeting, Jun 13, 2024

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Price target decreased by 8.0% to US$20.25

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Chief Scientific Officer exercised options to buy US$212k worth of stock.

Caribou Biosciences: Under The Radar With Catalysts Approaching

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer

Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Consensus revenue estimates increase by 71%

Price target decreased by 7.8% to US$22.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board

Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Caribou Biosciences, Inc. Appoints Reigin Zawadzki as Chief People Officer

Consensus revenue estimates decrease by 19%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.4% to US$24.86

Price target decreased by 8.6% to US$25.14

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

New minor risk - Shareholder dilution

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Caribou Biosciences, Inc

Pomerantz Law Firm Announces the Filing of A Class Action Against Caribou Biosciences, Inc

Caribou Biosciences, Inc. Appoints Jason V. O'Byrne as Principal Accounting Officer

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

Chief Scientific Officer exercised options to buy US$206k worth of stock.

Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy and Fast Track Designations to Cb-010, an Allogeneic Anti-Cd19 Car-T Cell Therapy

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-Bcma Car-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences Presents Case Report on Long-Term Follow Up of First Patient Dosed in Phase 1 Antler Trial At the Lymphoma, Leukemia, & Myeloma Congress 2022

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Vice President of Finance & Controller recently sold US$108k worth of stock

Insider exercised options to buy US$314k worth of stock.

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Chief Scientific Officer exercised options and sold US$369k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caribou Biosciences: Potential To Change CAR-T Landscape

Caribou Biosciences, Inc. Announces Board Changes

Caribou Biosciences, Inc., Annual General Meeting, Sep 20, 2022

Caribou Biosciences, Inc.(NasdaqGS:CRBU) dropped from Russell 2000 Growth Index

Caribou Biosciences, Inc. Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress